| Product NDC: | 0185-0713 |
| Proprietary Name: | Orphenadrine Citrate, Aspirin and Caffeine |
| Non Proprietary Name: | Orphenadrine Citrate, Aspirin and Caffeine |
| Active Ingredient(s): | 385; 30; 25 mg/1; mg/1; mg/1 & nbsp; Orphenadrine Citrate, Aspirin and Caffeine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, MULTILAYER |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0185-0713 |
| Labeler Name: | Eon Labs, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA074654 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19961231 |
| Package NDC: | 0185-0713-05 |
| Package Description: | 500 TABLET, MULTILAYER in 1 BOTTLE (0185-0713-05) |
| NDC Code | 0185-0713-05 |
| Proprietary Name | Orphenadrine Citrate, Aspirin and Caffeine |
| Package Description | 500 TABLET, MULTILAYER in 1 BOTTLE (0185-0713-05) |
| Product NDC | 0185-0713 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Orphenadrine Citrate, Aspirin and Caffeine |
| Dosage Form Name | TABLET, MULTILAYER |
| Route Name | ORAL |
| Start Marketing Date | 19961231 |
| Marketing Category Name | ANDA |
| Labeler Name | Eon Labs, Inc. |
| Substance Name | ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE |
| Strength Number | 385; 30; 25 |
| Strength Unit | mg/1; mg/1; mg/1 |
| Pharmaceutical Classes | Centrally-mediated Muscle Relaxation [PE],Muscle Relaxant [EPC],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE],Methylxanthine [EPC],Xanthines [Chemical/Ingredient] |